Stock Movers
Stock Movers

Jul 10, 2026 · 5 min

Meta jumps and Forte Biosciences surges while Paramount Skydance slides on debt

Weekly Roundup: Meta's Big Week, Paramount Skydance Mixed, Forte Biosciences Soars

Understanding the divergent drivers behind weekly market movers reveals how tech earnings, corporate debt, and clinical trial results rapidly reshape investor sentiment.

3 key takeaways
  1. 1Meta secured a major weekly win with a fifteen percent stock jump boosting tech sector confidence.
  2. 2Paramount Skydance shares slid significantly as investors reacted to mounting concerns over the company's debt.
  3. 3Forte Biosciences experienced a massive stock surge fueled by positive clinical data for its pipeline.

The brief

Bloomberg News equities reporter Avalon Purnell joins the program to break down a highly volatile week in the stock market, highlighting three companies experiencing massive, news-driven valuation swings.

Meta led the tech sector with an impressive fifteen percent stock jump, while Paramount Skydance faced a significant slide as investors grew increasingly anxious over the entertainment giant's debt concerns.

In the biotech space, clinical-stage biopharmaceutical firm Forte Biosciences stole the spotlight, experiencing a massive trading surge following the release of highly positive clinical data.

What was said on this episode

3 statements · 3 positive

  1. Forte Biosciences reported positive early-stage clinical data for its vitiligo drug.

    “reporting some pretty positive early stage clinical data for its Vitiligo drug”

    Listen at 2:42

  2. Forte Biosciences’ clinical data lifted peers including First Tracks Biotherapeutics.

    “it also pushed up some of its peers as well, like First Tracks Biotherapeutics, which is pursuing a similar molecule for a different therapy area”

    Listen at 2:46

  3. Avalon Purnellon Early-stage biotech clinical dataPositive3:10

    Biotechs need strong early-stage data to attract interest from large pharmaceutical companies.

    “You have to have some good early stage data that gets the likes of a big pharma name like an Eli Lilly interested”

    Listen at 3:10

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Books & mentions

Weekly email

State of the Pod, every Monday

The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.

Listen to the full episode and explore every guest, topic, and moment on PodLume.